FDA panel votes to place popular peptide BPC-157 on compounding list
23/07/2026 17:42
FDA panel votes to place popular peptide BPC-157 on compounding list July 23 (Reuters) - A panel of advisers to the U.S. Food and Drug Administration on Thursday voted to place a widely used peptide called BPC-157 on a list that would allow broader pharmacy compounding.
Eight panel members voted in favor, while six members voted against it. One member abstained.
(Reporting by Sriparna Roy, Sneha S K in Bengaluru, Amina Niasse in New York; Editing by Joyjeet Das)
Recent news on Hims & Hers Health
See all newsBrief: Hims & Hers Health Expands Testosterone Care With Injectable And Oral TRT
Hims & Hers Health launches online weight management service for men in Germany
Corrected: US FDA takes step to change peptide compounding policy (Oct 15)
Brief: Hims & Hers Names Jon Franklin As Chief Accounting Officer
Brief: Hims & Hers Names Chief Medical Officers In The Uk And Australia, Deepening Its Investment In Local Clinical Leadership